The company struggles to move the needle at the SITC meeting with an up-to-date cut of its first-line melanoma trial of NKTR-214 and Opdivo.
The abstract of the company’s Pivot-02 trial in first-line melanoma, due to be presented in full at SITC on Friday, looks disappointing.
An important test of Nektar’s cytokine agonist approaches, though some investors have already decided that Bristol-Myers Squibb was wrong to endorse it earlier this year.
Higher-risk novel drug development is chosen over lower-cost volume play as US biosimilar growth continues to sputter.
A US complete response letter leaves Ruconest at the mercy of rivals like Shire.
Deciphera Pharmaceuticals emerges as one of the Asco 2018 winner as Jounce Therapeutics falls on weak data.
Loxo impresses with its targeted therapy, but Nektar is punished for confusing data.
Galapagos hopes Pelican and Falcon will fly, and Amgen needs a yes for its third most valuable pipeline asset.